Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Oct 2;13(1):131.
doi: 10.1186/s13045-020-00968-1.

Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia

Guido Lancman  1 , John Mascarenhas  1 , Michal Bar-Natan  2
Affiliations
Case Reports

Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia

Guido Lancman et al. J Hematol Oncol. .

Abstract

SARS-CoV-2 has infected millions of people worldwide, but little is known at this time about second infections or reactivation. Here, we report a case of a 55-year-old female undergoing treatment for CD20+ B cell acute lymphoblastic leukemia who experienced a viral reactivation after receiving rituximab, cytarabine, and dasatinib. She was initially hospitalized with COVID-19 in April and developed a high antibody titer with two negative nasal polymerase chain reaction (PCR) swabs for SARS-CoV-2 on discharge. After recovery, she resumed treatment in June for her leukemia, which included rituximab, cytarabine, and dasatinib. She promptly lost her COVID-19 antibodies, and her nasal PCR turned positive in June. She developed a severe COVID-19 pneumonia with lymphopenia, high inflammatory markers, and characteristic bilateral ground-glass opacities on chest CT, requiring high-flow nasal cannula and transfer to the intensive care unit. She received steroids, anticoagulation, and convalescent plasma, and within 48 h she was off oxygen. She was discharged home in stable condition several days later. Given the short time frame from leukemia treatment to PCR positivity and the low case rate in mid-June in New York City, reinfection appears to have been unlikely and SARS-CoV-2 reactivation is a possible explanation. This case illustrates the risks of treating recently recovered COVID-19 patients with immunosuppressive therapy, particularly lymphocyte- and antibody-depleting therapy, and raises new questions about the potential of SARS-CoV-2 reactivation.

Keywords: COVID-19; Cytarabine; Reactivation; Rituximab; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Xiao AT, Tong YX, Zhang S. False-negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: rather than recurrence. J Med Virol. 2020 doi: 10.1002/jmv.25855. - DOI - PMC - PubMed
    1. Yuan J, Kou S, Liang Y, et al. PCR assays turned positive in 25 discharged COVID-19 patients. Clin Infect Dis. 2020;ciaa398. - PMC - PubMed
    1. Ye G, Pan Z, Pan Y, et al. Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation. J Infect. 2020;80(5):e14–e17. doi: 10.1016/j.jinf.2020.03.001. - DOI - PMC - PubMed
    1. Ravioli S, Ochsner H, Lindner G. Reactivation of COVID-19 pneumonia: a report of two cases. J Infect. 2020;S0163–4453(20):30279–30286. - PMC - PubMed
    1. Rousselot P, Coudé MM, Gokbuget N, et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL. Blood. 2016;128(6):774–782. doi: 10.1182/blood-2016-02-700153. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources